{
    "clinical_study": {
        "@rank": "33280", 
        "arm_group": {
            "arm_group_label": "RoActemra/Actemra", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This long-term, open-label extension study will evaluate the safety of RoActemra/Actemra\n      (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis who\n      completed the WA19977 core study. Patients will continue to receive RoActemra/Actemra 8\n      mg/kg intravenously every 4 weeks. Anticipated time on study treatment is 104 weeks."
        }, 
        "brief_title": "A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Juvenile Idiopathic Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Juvenile Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who completed visit 33 (week 104) of WA19977 study and who may benefit from\n             study drug treatment according to the investigator's assessment\n\n          -  Patients have to receive the first RoActemra/Actemra infusion in this study at the\n             Week 8 visit at the latest\n\n          -  Females of child-bearing potential and males with female partners of child-bearing\n             potential must agree to use effective contraception as defined by protocol\n\n        Exclusion Criteria:\n\n          -  Patients with, according to investigator judgment, not satisfactory benefit from\n             RoActemra/Actemra therapy within WA19977\n\n          -  Treatment with any investigational agent since the last administration of study drug\n             in the core study WA19977\n\n          -  Patient developed any other autoimmune rheumatic disease or overlap syndrome other\n             than the permitted polyarticular-course JIA subsets: rheumatoid factor positive or\n             negative JIA or extended oligoarticular JIA\n\n          -  Patient is pregnant , lactating, or intending to become pregnant during the study and\n             up to 12 weeks after the last administration of study drug\n\n          -  Any significant concomitant disease or medical or surgical condition\n\n          -  History of significant allergic or infusion reactions to prior biologic therapy\n\n          -  Currently active primary or secondary immunodeficiency\n\n          -  Any infections with contraindications to RoActemra/Actemra therapy according to\n             investigator judgment\n\n          -  Inadequate hepatic, renal or bone marrow function"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "4 Years"
        }, 
        "enrollment": {
            "#text": "7", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01673919", 
            "org_study_id": "ML28166", 
            "secondary_id": "2011-005515-90"
        }, 
        "intervention": {
            "arm_group_label": "RoActemra/Actemra", 
            "description": "8 mg/kg iv every 4 weeks, 104 weeks", 
            "intervention_name": "tocilizumab [RoActemra/Actemra]", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Le Kremlin Bic\u00eatre", 
                        "country": "France", 
                        "zip": "94275"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34295"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75743"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75679"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis From France Who Completed the Global, Multinational Trial (WA19977)", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curite du M\u00e9dicament et des Produits de Sant\u00e9 - ANSM"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Long-term safety: Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "approximately 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01673919"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Response rates according to the American College of Rheumatology criteria for juvenile idiopathic arthritis (JIA ACR)", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "measure": "Proportion of patients achieving inactive disease/clinical remission", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}